Live attenuated HIV vaccines: predicting the tradeoff between efficacy and safety.
about
Role of CCL3L1-CCR5 genotypes in the epidemic spread of HIV-1 and evaluation of vaccine efficacy.Live, attenuated simian immunodeficiency virus SIVmac-M4, with point mutations in the Env transmembrane protein intracytoplasmic domain, provides partial protection from mucosal challenge with pathogenic SIVmac251.Divergence, not diversity of an attenuated equine lentivirus vaccine strain correlates with protection from diseaseEnvelope determinants of equine lentiviral vaccine protection.Comparative Immunogenicity of Evolved V1V2-Deleted HIV-1 Envelope Glycoprotein TrimersA macromolecular delivery vehicle for protein-based vaccines: acid-degradable protein-loaded microgelsEmerging vaccine informatics.Immune suppression of challenged vaccinates as a rigorous assessment of sterile protection by lentiviral vaccines.Potential public health impact of new tuberculosis vaccinesEnvelope variation as a primary determinant of lentiviral vaccine efficacy.Mathematical insights in evaluating state dependent effectiveness of HIV prevention interventions.AIDS vaccination studies using an ex vivo feline immunodeficiency virus model: protection from an intraclade challenge administered systemically or mucosally by an attenuated vaccine.Predicting the impact of a partially effective HIV vaccine and subsequent risk behavior change on the heterosexual HIV epidemic in low- and middle-income countries: A South African example.Predicting the impact of a nonsterilizing vaccine against human immunodeficiency virus.HIV vaccines: a brief overview.Bayesian calibration of a natural history model with application to a population model for colorectal cancer.
P2860
Q33383193-504529D3-0D66-4927-BC05-B2004BC738F4Q34354961-D63FFD45-DC36-4ABB-B400-E0937E5E48A2Q34380211-2231915D-103A-4C64-912E-B7BD13D8C259Q34778836-25BD82E5-FE04-4002-AD26-B182BAB16149Q34807480-CC281403-BB48-4B6B-B44B-1FEE6398751DQ34981649-CE442F3F-AFBB-4DC4-9FDA-D5835714F7EBQ35100809-A9DEDFA5-1020-4CF2-B6DE-3299BC2B06FBQ35758001-A0FC8FF1-FEEF-4868-9158-3EEDA530FC0AQ35872932-BC0D125C-6BB8-43BF-927F-0D22B6CA8728Q36002639-1FF7762E-B090-4DD3-9660-4137F13F7D41Q36274199-2D7D8AB1-4CDC-4365-99EB-18F2B9AF3F9FQ36473694-F3354010-61F0-4177-BABD-B121B893D0EBQ36603971-4146FBED-9D77-4C62-AE9B-D5FFD646EDC7Q37568241-E09DE96D-E4EA-4013-960D-DE80B147EBD1Q38210557-766B5A7E-4F2F-4223-AB03-7534A8F0EC25Q51628329-FF2C425E-D000-40E0-A6E8-101EA2D6673A
P2860
Live attenuated HIV vaccines: predicting the tradeoff between efficacy and safety.
description
2001 nî lūn-bûn
@nan
2001 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի մարտին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Live attenuated HIV vaccines: predicting the tradeoff between efficacy and safety.
@ast
Live attenuated HIV vaccines: predicting the tradeoff between efficacy and safety.
@en
Live attenuated HIV vaccines: predicting the tradeoff between efficacy and safety.
@nl
type
label
Live attenuated HIV vaccines: predicting the tradeoff between efficacy and safety.
@ast
Live attenuated HIV vaccines: predicting the tradeoff between efficacy and safety.
@en
Live attenuated HIV vaccines: predicting the tradeoff between efficacy and safety.
@nl
prefLabel
Live attenuated HIV vaccines: predicting the tradeoff between efficacy and safety.
@ast
Live attenuated HIV vaccines: predicting the tradeoff between efficacy and safety.
@en
Live attenuated HIV vaccines: predicting the tradeoff between efficacy and safety.
@nl
P2093
P2860
P356
P1476
Live attenuated HIV vaccines: predicting the tradeoff between efficacy and safety.
@en
P2093
P2860
P304
P356
10.1073/PNAS.061029998
P407
P577
2001-03-01T00:00:00Z